OPKO Health, Inc. Cost of Revenue
OPKO Health, Inc. (OPK) reported Cost of Revenue of $83.56 million for the 3-month period ending 2026-06-30, per its 10-Q/A filed 2026-08-28.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-28
- OPKO Health, Inc. cost of goods and services sold for the quarter ending 2026-06-30 was $83.56M, a 22.20% decline year-over-year.
- OPKO Health, Inc. cost of goods and services sold for the quarter ending 2026-03-31 was $78.44M, a 26.92% decline year-over-year.
- OPKO Health, Inc. cost of goods and services sold for the quarter ending 2025-12-31 was $84.42M, a 14.70% decline year-over-year.
- OPKO Health, Inc. cost of goods and services sold for the quarter ending 2025-09-30 was $101.78M, a 23.77% decline year-over-year.
- OPKO Health, Inc. cost of goods and services sold for fiscal 2025 was $400.94M, a 18.94% decline from fiscal 2024.
- OPKO Health, Inc. cost of goods and services sold for fiscal 2024 was $494.63M, a 9.30% decline from fiscal 2023.
- OPKO Health, Inc. cost of goods and services sold for fiscal 2023 was $545.37M, a 23.83% decline from fiscal 2022.
- OPKO Health, Inc. cost of goods and services sold for fiscal 2022 was $715.98M.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 3 month as first filed | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 6 month as first filed | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month | Cost of Goods and Services Sold 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $83.56M 10-Q/A · filed 2026-08-28 | $162.00M 10-Q/A · filed 2026-08-28 | $246.43M derived: sum of 3 quarters · filed 2026-08-28 | $348.20M derived: sum of 4 quarters · filed 2026-08-28 | |||
| 2026-03-31 | $78.44M 10-Q/A · filed 2026-08-28 | $162.87M derived: sum of 2 quarters · filed 2026-08-28 | $264.64M derived: sum of 3 quarters · filed 2026-08-28 | $372.05M derived: sum of 4 quarters · filed 2026-08-28 | |||
| 2025-12-31 | $84.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $186.20M derived: sum of 2 quarters · filed 2026-02-26 | $293.61M derived: sum of 3 quarters · filed 2026-08-28 | $400.94M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $101.78M 10-Q · filed 2025-10-29 | $209.18M derived: sum of 2 quarters · filed 2026-08-28 | $316.51M 10-Q · filed 2025-10-29 | $415.49M derived: sum of 4 quarters · filed 2026-08-28 | |||
| 2025-06-30 | $107.41M 10-Q/A · filed 2026-08-28 | $214.74M 10-Q/A · filed 2026-08-28 | $313.72M derived: sum of 3 quarters · filed 2026-08-28 | $447.22M derived: sum of 4 quarters · filed 2026-08-28 | |||
| 2025-03-31 | $107.33M 10-Q/A · filed 2026-08-28 | $206.31M derived: sum of 2 quarters · filed 2026-08-28 | $339.81M derived: sum of 3 quarters · filed 2026-08-28 | $470.35M derived: sum of 4 quarters · filed 2026-08-28 | |||
| 2024-12-31 | $98.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $232.48M derived: sum of 2 quarters · filed 2026-02-26 | $363.01M derived: sum of 3 quarters · filed 2026-02-26 | $494.63M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $133.50M 10-Q · filed 2025-10-29 | $264.04M derived: sum of 2 quarters · filed 2025-10-29 | $395.65M 10-Q · filed 2025-10-29 | ||||
| 2024-06-30 | $130.53M 10-Q · filed 2025-07-31 | $262.15M 10-Q · filed 2025-07-31 | |||||
| 2024-03-31 | $131.62M 10-Q · filed 2025-05-01 | ||||||
| 2023-12-31 | $545.37M 10-K · filed 2026-02-26 | ||||||
| 2022-12-31 | $715.98M 10-K · filed 2025-03-03 | ||||||
| 2016-12-31 | $564.10M 10-K · filed 2017-03-01 | ||||||
| 2015-12-31 | $193.31M 10-K · filed 2017-03-01 | ||||||
| 2015-06-30 | $14.43M 10-Q · filed 2015-08-05 | $24.75M 10-Q · filed 2015-08-05 | -$1.95M derived: sum of 3 quarters · filed 2017-03-01 | $9.17M derived: sum of 4 quarters · filed 2017-03-01 | |||
| 2015-03-31 | $10.32M 10-Q · filed 2015-05-11 | -$16.38M derived: sum of 2 quarters · filed 2017-03-01 | -$5.26M derived: sum of 3 quarters · filed 2017-03-01 | $7.30M derived: sum of 4 quarters · filed 2017-03-01 | |||
| 2014-12-31 | -$26.70M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$15.58M derived: sum of 2 quarters · filed 2017-03-01 | -$3.02M derived: sum of 3 quarters · filed 2017-03-01 | $9.37M 10-K · filed 2017-03-01 | $48.01M 10-K · filed 2015-02-27 | ||
| 2014-09-30 | $11.12M 10-Q · filed 2014-11-07 | $23.68M derived: sum of 2 quarters · filed 2015-08-05 | $36.08M 10-Q · filed 2014-11-07 | $9.68M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-06-30 | $12.56M 10-Q · filed 2015-08-05 | $24.95M 10-Q · filed 2015-08-05 | -$1.44M derived: sum of 3 quarters · filed 2016-02-29 | $10.52M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-03-31 | $12.39M 10-Q · filed 2015-05-11 | -$14.00M derived: sum of 2 quarters · filed 2016-02-29 | -$2.05M derived: sum of 3 quarters · filed 2016-02-29 | $11.05M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2013-12-31 | -$26.39M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | -$14.44M derived: sum of 2 quarters · filed 2016-02-29 | -$1.34M derived: sum of 3 quarters · filed 2016-02-29 | $10.42M 10-K · filed 2016-02-29 | $48.86M 10-K · filed 2014-03-03 | ||
| 2013-09-30 | $11.95M 10-Q · filed 2014-11-07 | $25.05M derived: sum of 2 quarters · filed 2014-11-07 | $36.81M 10-Q · filed 2014-11-07 | $45.66M derived: sum of 4 quarters · filed 2015-02-27 | |||
| 2013-06-30 | $13.10M 10-Q · filed 2014-08-11 | $24.86M 10-Q · filed 2014-08-11 | $33.71M derived: sum of 3 quarters · filed 2015-02-27 | $41.20M derived: sum of 4 quarters · filed 2015-02-27 | |||
| 2013-03-31 | $11.76M 10-Q · filed 2014-05-09 | $20.61M derived: sum of 2 quarters · filed 2015-02-27 | $28.09M derived: sum of 3 quarters · filed 2015-02-27 | $34.65M derived: sum of 4 quarters · filed 2015-02-27 | |||
| 2012-12-31 | $8.85M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $16.34M derived: sum of 2 quarters · filed 2015-02-27 | $22.89M derived: sum of 3 quarters · filed 2015-02-27 | $27.88M 10-K · filed 2015-02-27 | |||
| 2012-09-30 | $7.49M 10-Q · filed 2013-11-12 | $14.04M derived: sum of 2 quarters · filed 2013-11-12 | $19.03M 10-Q · filed 2013-11-12 | $23.19M derived: sum of 4 quarters · filed 2014-03-03 | |||
| 2012-06-30 | $6.55M 10-Q · filed 2013-08-09 | $11.54M 10-Q · filed 2013-08-09 | $15.70M derived: sum of 3 quarters · filed 2014-03-03 | $19.72M derived: sum of 4 quarters · filed 2014-03-03 | |||
| 2012-03-31 | $4.99M 10-Q · filed 2013-05-10 | $9.14M derived: sum of 2 quarters · filed 2014-03-03 | $13.16M derived: sum of 3 quarters · filed 2014-03-03 | $18.05M derived: sum of 4 quarters · filed 2014-03-03 | |||
| 2011-12-31 | $4.16M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | $8.18M derived: sum of 2 quarters · filed 2014-03-03 | $13.06M derived: sum of 3 quarters · filed 2014-03-03 | $17.24M 10-K · filed 2014-03-03 | |||
| 2011-09-30 | $4.02M 10-Q · filed 2012-11-09 | $8.91M derived: sum of 2 quarters · filed 2012-08-09 | $13.09M 10-Q · filed 2012-11-09 | $16.43M derived: sum of 4 quarters · filed 2013-03-18 | |||
| 2011-06-30 | $4.89M 10-Q · filed 2012-08-09 | $6.21M 10-Q · filed 2011-08-08 | $9.07M 10-Q · filed 2012-08-09 | $11.83M 10-Q · filed 2011-08-08 | $12.42M derived: sum of 3 quarters · filed 2013-03-18 | $15.77M derived: sum of 4 quarters · filed 2013-03-18 | |
| 2011-03-31 | $4.18M 10-Q · filed 2012-05-10 | $7.53M derived: sum of 2 quarters · filed 2013-03-18 | $10.88M derived: sum of 3 quarters · filed 2013-03-18 | $15.73M derived: sum of 4 quarters · filed 2013-03-18 | |||
| 2010-12-31 | $3.35M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $6.70M derived: sum of 2 quarters · filed 2013-03-18 | $11.55M derived: sum of 3 quarters · filed 2013-03-18 | $13.49M 10-K · filed 2013-03-18 | |||
| 2010-09-30 | $3.35M 10-Q · filed 2011-11-09 | $8.20M derived: sum of 2 quarters · filed 2011-11-09 | $10.14M 10-Q · filed 2011-11-09 | ||||
| 2010-06-30 | $4.85M 10-Q · filed 2011-08-08 | $10.38M 10-Q · filed 2011-08-08 | |||||
| 2009-12-31 | $2.88M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |